<turbo-stream action="append" target="news"><template>  <div class="row mb-4 py-2 news-box">
  <div class="col-12 col-md-8 col-lg-9 order-md-1 order-2">
    <div class="news-box__info-line mb-2">
        <span class="me-2 new badge text-success bg-green-100">
          Positive
        </span>
        <div class="me-2"><a class="text-gray" data-turbo-frame="_top" href="/en/stock/Novo-Nordisk-DK0062498333">Novo Nordisk</a></div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">Market Watch</div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">about one month ago</div>
    </div>

    <div class="mb-2">
      <a target="_blank" rel="nofollow" href="https://www.marketwatch.com/story/novo-nordisk-strikes-second-licensing-deal-since-frosty-capital-markets-day-cc0db878">Novo Nordisk strikes second licensing deal since frosty capital-markets day</a>
    </div>

      <div class="me-0 me-md-5">
        Novo Nordisk on Tuesday struck its second licensing deal since receiving a poor reception from investors after presenting its long-term strategy.
      </div>
  </div>

  <div class="col-12 col-md-4 col-lg-3 order-md-2 order-1">
  </div>
</div>

  <div class="row mb-4 py-2 news-box">
  <div class="col-12 col-md-8 col-lg-9 order-md-1 order-2">
    <div class="news-box__info-line mb-2">
        <span class="me-2 new badge text-success bg-green-100">
          Positive
        </span>
        <div class="me-2"><a class="text-gray" data-turbo-frame="_top" href="/en/stock/Novo-Nordisk-DK0062498333">Novo Nordisk</a></div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">WSJ</div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">about one month ago</div>
    </div>

    <div class="mb-2">
      <a target="_blank" rel="nofollow" href="https://www.wsj.com/health/pharma/novo-inks-weight-loss-licensing-deal-with-hengrui-pharma-bd3d4f1c">Novo Inks Weight-Loss Licensing Deal With Hengrui Pharma</a>
    </div>

      <div class="me-0 me-md-5">
        The Danish drugmaker signed a licensing deal for a weight-loss treatment being developed by Hengrui Pharma that could be worth up to $2.6 billion.
      </div>
  </div>

  <div class="col-12 col-md-4 col-lg-3 order-md-2 order-1">
  </div>
</div>

  <div class="row mb-4 py-2 news-box">
  <div class="col-12 col-md-8 col-lg-9 order-md-1 order-2">
    <div class="news-box__info-line mb-2">
        <span class="me-2 new badge text-success bg-green-100">
          Positive
        </span>
        <div class="me-2"><a class="text-gray" data-turbo-frame="_top" href="/en/stock/Novo-Nordisk-DK0062498333">Novo Nordisk</a></div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">Reuters</div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">about one month ago</div>
    </div>

    <div class="mb-2">
      <a target="_blank" rel="nofollow" href="https://www.reuters.com/legal/litigation/chinas-hengrui-inks-up-26-billion-deal-with-novo-nordisk-obesity-drug-2026-09-29/">China&#39;s Hengrui inks up to $2.6 billion deal with Novo Nordisk for obesity drug</a>
    </div>

      <div class="me-0 me-md-5">
        Jiangsu Hengrui Pharmaceuticals , China&#39;s ​largest drugmaker by ‌market value, said on Tuesday it ​will license ​global rights to ⁠its weight-management drug ​HRS-1596 to ​Novo Nordisk A/S in a deal worth ​up to $2.6 ​billion.
      </div>
  </div>

  <div class="col-12 col-md-4 col-lg-3 order-md-2 order-1">
  </div>
</div>

  <div class="row mb-4 py-2 news-box">
  <div class="col-12 col-md-8 col-lg-9 order-md-1 order-2">
    <div class="news-box__info-line mb-2">
        <span class="me-2 new badge text-secondary bg-gray-200">
          Neutral
        </span>
        <div class="me-2"><a class="text-gray" data-turbo-frame="_top" href="/en/stock/Novo-Nordisk-DK0062498333">Novo Nordisk</a></div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">ETF Trends</div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">about one month ago</div>
    </div>

    <div class="mb-2">
      <a target="_blank" rel="nofollow" href="https://www.etftrends.com/thematic-investing-content-hub/nthm-index-rebalance-works-thematic-rotation/">NTHM&#39;s Index Rebalance Puts Thematic Rotation to Work</a>
    </div>

      <div class="me-0 me-md-5">
        The latest rebalance of VettaFi&#39;s Thematic Rotation Quality Momentum Screened Index (TQRMS), tracked by the NBI Thematic Rotation ETF (NTHM:TSX), reshapes the portfolio around a new set of themes. GLP-1 weight loss drug manufacturers and midstream energy join the index, while battery technology &amp; storage and software-as-a-service (SaaS) exit.
      </div>
  </div>

  <div class="col-12 col-md-4 col-lg-3 order-md-2 order-1">
  </div>
</div>

  <div class="row mb-4 py-2 news-box">
  <div class="col-12 col-md-8 col-lg-9 order-md-1 order-2">
    <div class="news-box__info-line mb-2">
        <span class="me-2 new badge text-secondary bg-gray-200">
          Neutral
        </span>
        <div class="me-2"><a class="text-gray" data-turbo-frame="_top" href="/en/stock/Novo-Nordisk-DK0062498333">Novo Nordisk</a></div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">CNBC</div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">about one month ago</div>
    </div>

    <div class="mb-2">
      <a target="_blank" rel="nofollow" href="https://www.cnbc.com/2026/09/25/novo-eli-lilly-obesity-drugs.html">Novo is betting on its next chapter as Eli Lilly gains more ground in GLP-1s</a>
    </div>

      <div class="me-0 me-md-5">
        Novo this week laid out an ambitious strategy to reignite growth beyond its top-selling Wegovy and Ozempic injections, but faces an uphill battle to win back investors and obesity market share. Meanwhile, Lilly continues to chip away at the company&#39;s position in the market – including in the burgeoning obesity pill space.
      </div>
  </div>

  <div class="col-12 col-md-4 col-lg-3 order-md-2 order-1">
  </div>
</div>

  <div class="row mb-4 py-2 news-box">
  <div class="col-12 col-md-8 col-lg-9 order-md-1 order-2">
    <div class="news-box__info-line mb-2">
        <span class="me-2 new badge text-success bg-green-100">
          Positive
        </span>
        <div class="me-2"><a class="text-gray" data-turbo-frame="_top" href="/en/stock/Novo-Nordisk-DK0062498333">Novo Nordisk</a></div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">CNBC</div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">about one month ago</div>
    </div>

    <div class="mb-2">
      <a target="_blank" rel="nofollow" href="https://www.cnbc.com/2026/09/25/wegovy-novo-nordisk-obesity-drugs.html">Pharma stock soars 150% on injectables deal with Wegovy maker Novo</a>
    </div>

      <div class="me-0 me-md-5">
        The Swedish drug-delivery company agreed to license its PharmaShell technology to Novo Nordisk for up to five development programs targeting obesity, type 2 diabetes and other cardiometabolic conditions. Novo Nordisk will use the technology to develop injectable drugs that could be administered monthly or quarterly, with Nanexa eligible for upfront and milestone payments as well as royalties on...
      </div>
  </div>

  <div class="col-12 col-md-4 col-lg-3 order-md-2 order-1">
  </div>
</div>

  <div class="row mb-4 py-2 news-box">
  <div class="col-12 col-md-8 col-lg-9 order-md-1 order-2">
    <div class="news-box__info-line mb-2">
        <span class="me-2 new badge text-success bg-green-100">
          Positive
        </span>
        <div class="me-2"><a class="text-gray" data-turbo-frame="_top" href="/en/stock/Novo-Nordisk-DK0062498333">Novo Nordisk</a></div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">Market Watch</div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">about one month ago</div>
    </div>

    <div class="mb-2">
      <a target="_blank" rel="nofollow" href="https://www.marketwatch.com/story/after-capital-markets-day-flop-novo-strikes-licensing-deal-that-sends-a-swedish-companys-stock-soaring-f3c99cbe">After capital-markets day flop, Novo strikes licensing deal that sends a Swedish company&#39;s stock soaring</a>
    </div>

      <div class="me-0 me-md-5">
        Just days after a capital-markets day left investors wondering what&#39;s next for Novo Nordisk, the Danish drug giant struck a licensing deal worth over $1 billion.
      </div>
  </div>

  <div class="col-12 col-md-4 col-lg-3 order-md-2 order-1">
  </div>
</div>

  <div class="row mb-4 py-2 news-box">
  <div class="col-12 col-md-8 col-lg-9 order-md-1 order-2">
    <div class="news-box__info-line mb-2">
        <span class="me-2 new badge text-success bg-green-100">
          Positive
        </span>
        <div class="me-2"><a class="text-gray" data-turbo-frame="_top" href="/en/stock/Novo-Nordisk-DK0062498333">Novo Nordisk</a></div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">WSJ</div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">about one month ago</div>
    </div>

    <div class="mb-2">
      <a target="_blank" rel="nofollow" href="https://www.wsj.com/health/pharma/novo-nordisk-to-pay-up-to-1-3-billion-for-nanexas-drug-delivery-technology-395b3770">Novo Nordisk to Pay Up to $1.3 Billion for Nanexa&#39;s Drug Delivery Technology</a>
    </div>

      <div class="me-0 me-md-5">
        Novo Nordisk agreed to license and develop the technology, which could cut the frequency patients need to inject its obesity and diabetes drugs.
      </div>
  </div>

  <div class="col-12 col-md-4 col-lg-3 order-md-2 order-1">
  </div>
</div>

</template></turbo-stream><turbo-stream action="replace" target="link"><template><div id="link">
    <a class="btn btn-outline-primary btn--small" data-turbo-stream="" href="/en/news/Novo-Nordisk-DK0062498333/load_more?page=5">
      Show more News
      <i class="fa fa-arrow-down fa-fw"></i>
</a></div>
</template></turbo-stream>